The place of sotalol in the treatment of extrasystole in patients with hypertension


  • V.P. Ivanov
  • L.M. Bulat
  • O.V. Lysunets
  • N.V. Didik
Keywords: sotalol, hypertension, extrasystole.

Abstract

Annotation. The spread of hypertension in the world encourages the search for new methods for its diagnosis and treatment. And the problem of treating patients with cardiac arrhythmias is that antiarrhythmic drugs of various classes used by doctors of practical health care have proarrhythmogenic properties. And this increases the possibility of the development of lethal cardiovascular events. From this perspective, the parameters for the effect on the morphofunctional parameters of the myocardium, highlighted in this article, when using the antiarrhythmic drug III sotalol, which has the properties of a beta-blocker, are relevant and justified. The purpose of the study was to study the effect of sotalol on the morphological and functional parameters of the myocardium with a combination of stage II hypertension and extrasystole of various topics in patients of different age groups and gender content. We examined 120 people with stage II hypertension (42 men and 78 women) aged 27 to 81 years (average age 59.8 years) and extrasystole of various topics and 30 people (13 men and 17 women) aged 30 to 76 years old (average age — 56.4) with stage II hypertension, in accordance with the Recommendations of the Ukrainian Association of Cardiology, without signs of extrasystole. The first clinical group was formed by 54 (45%) patients with supraventricular extrasystoles, the second — 42 (35%) patients with ventricular extrasystoles, the third — 24 (20%) with combined supraventricular and ventricular extrasystoles. Statistical analysis of the results of the study was performed using methods of variational statistics using the programs MicroSoft Exel 2003 and StatSoft “Statistica” v. 10.0. The regularities of such indicators of structural and geometric remodeling of the left ventricle in patients with isolated hypertension, hypertension and extrasystole of various topics, the nature of remodeling of the left ventricle, analysis of changes in intracardiac hemodynamics over 6 months of taking sotalol by the above-mentioned patients are established. It was established that in patients with hypertension and with hypertension and supraventricular extrasystole concentric hypertrophy of the left ventricle predominates, in patients with hypertension and ventricular extrasystole eccentric remodeling, in patients with hypertension and combined extrasystole, is eccentric concentric remodeling of the left ventricle. It was established that the anti-remodeling effect of sotalol was reflected in the effect on the structural-geometric state of the left ventricle, and the analysis of the antiarrhythmic efficacy of sotalol allows us to recommend it as a basic treatment for patients with hypertension combined with extrasystole. The results demonstrated the effect of sotalol on the structural and functional state of the myocardium in patients with isolated hypertension and hypertension, combined with extrasystole.

References

1. Didyk, N. V. (2016). Dyslipidemiia u khvorykh na arterialnu hipertenziiu i ekstrasystoliiu [Dyslipidemia in patients with hypertension and extrasystole]. Visnyk Dnipropetrovskoho universytetu. Biolohiia. Medytsyna – Bulletin of Dnipropetrovsk University. Biology. Medicine, 7 (2), 73–78. Doi: 10.15421/021613.

2. Didyk, N. V. Osoblyvosti strukturnoho remodeliuvannia arterii pry hipertonichnii khvorobi II stadii ta ekstrasystolii [Features of structural remodeling of arteries in stage II hypertension and extrasystole]. Report of Morphology, 1 (21), 158–161.

3. Didyk, N. V., & Lysunets, O. V. Klinichni aspekty zastosuvannia Sotalolu [Clinical aspects of Sotalol administration]. Visnyk Vinnytskoho natsionalnoho medychnoho universytetu – Report of the Vinnitsa National Medical University, 2 (18), 629–632.

4. Eremina, M. A., Tregubov, V. G., Kanorskij, S. G., & Pokrovskij, V. M. (2016). Regulyatorno-adaptivnyj status v opredelenii effektivnosti bisoprolola i sotalola u pacientov s paroksizmalnoj fibrillyaciej predserdij i gipertonicheskoj boleznyu [Regulatory and adaptive status in determining the effectiveness of bisoprolol and sotalol in patients with paroxysmal atrial fibrillation and hypertension]. Arterialnaya gipertenziya – Arterial hypertension, 5 (22), 476–487. Doi: 10.18705/1607–419x–2016–22–5–476–487.

5. Lutai, M. I. (2016). Efektyvnist kombinovanoi terapii arterialnoi hipertenzii v Ukraini: rezultaty bahatotsentrovoho doslidzhennia TRIUMF [Effectiveness of combination therapy for hypertension in Ukraine: results of the triumph multicenter study]. Ukrainskyi kardiolohichnyi zhurnal – Ukrainian Cardiology Journal, 4, 17–28. Vziato z http://nbuv.gov.ua/UJRN/Ukzh_2016_4_3.

6. Yusupov, A. A., Kiyakbaev, G. K., Shavarov, A. A., & Moiseev, V. S. (2015). Vliyanie amiodarona i sotalola na morfofunkcionalnye parametry levogo predserdiya u bolnyh ishemicheskoj boleznyu serdca s recidiviruyushej fibrillyaciej predserdij [The effect of amiodarone and sotalol on the morphofunctional parameters of the left atrium in patients with coronary heart disease with recurrent atrial fibrillation]. Klinicheskaya farmakologiya i terapiya – Clinical Pharmacology and Therapy, 1, 38–43. http://www.fesmu.ru/elib/Article.aspx?id=313491.

7. Aguilar-Shea, A. L. (2016). The safety and efficacy of sotalol in the management of acute atrial fibrillation: a retrospective case control study. Interventional Cardiology, 8 (3), 637–642. Doi:10.4172/Interventional–Cardiology.1000529.

8. Batul, S. A., & Gopinathannair, R. (2017). Intravenous Sotalol-Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal. J. Atr. Fibrillation, 9 (5), 1499. Doi: 10.4022/jafib.1499.

9. Darpo, B., Karnad, D. R., Badilini, F., Florian, J., Garnett, C. E., Panisker, G. K., & Sarapa, N. (2014). Are women more susceptible than men to drug-induced QT prolongation. Concentration QTc modelling in a phase 1 study with oral rac-sotalol. Br. J. Clin. Pharmacol., 77, 522–531. doi: 10.1111/bcp.12201.

10. Didyk, N., & Lysunets, O. V. (2017). Changes in the arteries in the course of hypertensive disease and extrasystoles. Regulatory Mechanisms in Biosystems, 8 (1), 19–22. Doi: 10.15421/021704.

11. Ehrlich, C., & Tsu, L. V. (2015). Updates in antiarrhythmic therapy for atrial fibrillation in geriatric patients. Consult Pharm., 30 (2), 82–91. Doi: 10.4140/TCP.n.2015.82. Review.

12. January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E, Cleveland, J.C. Jr., & Yancy, C. W. (2014). AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. J. Am. Coll. Cardiol., 64, e1–e76.

13. Kpaeyeh Jr., J. A., & Wharton, J. M. (2016). Sotalol. Card Electrophysiol. Clin., 8 (2), 437–52. Doi: 10.1016/j.ccep.2016.02.007.

14. Lenhoff, H., Darpö, B., Ferber, G., Rosenqvist, M., & Frick M. (2016). Reduction over time of QTc prolongation in patients with sotalol after cardioversion of atrial fibrillation. Heart Rhythm., 13 (3), 661–8. doi: 10.1016/j.hrthm.2015.11.040.

15. Leung, A. A., Daskalopoulou, S. S., Dasgupta, K., McBrien, K., Butalia, S., & Zarnke, K. B. (2017). Hypertension Canada’s 2017 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Canadian Journal of Cardiology, 33 (5), 557–576. https://doi.org/10.1016/j.cjca.2017.03.005.

16. Milan, D. J., Saul, J. P., Somberg, J. C., & Molnar, J. (2017). Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiology, 136 (1), 52–60. DOI:10.1159/000447237.

17. Priori, G., Blomstrom-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, S., … Van Veldhuisen, D. S. (2015). ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrythmias and Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart J., Aug 29, 17. Doi: 10.1093 /eurheartj/ehv316.

18. Raiten, J. M., Ghadimi, K., Augoustides, J. G., Ramakrishna, H., Patel, P. A., Weiss, S. J., & Gutsche, J. T. (2015). Atrial fibrillation after cardiac surgery: clinical update on mechanisms and prophylactic strategies. J. Cardiothorac. Vasc. Anesth., 29 (3), 806–16. Doi: 10.1053/j.jvca.2015.01.001.

19. Redon, J., Mourad, J. J., Schmieder, R. E., Volpe, M., & Weiss, T. W. (2016). Why in 2016 are patients with hypertension not 100% controlled? A call to action. J. Hypertens., 34 (8), 1480–1488. https://doi.org/10.1097/HJH.0000000000000988.

20. Sardon, Blaye-Felice, Hamon, D., Sacher, F., Pascale, P., & Rollin, A. (2016). Premature ventricular contraction-induced cardiomyopathy: Related clinical and electrophysiologic parameters. Heart Rhythm., 13 (1), 103–110. https://doi.org/: 10.1016/j.hrthm.2015.08.025.

21. Schleifer, J. W., Sorajja, D., & Shen, W. K. (2015). Advances in the pharmacologic treatment of ventricular arrhythmias. Expert Opin Pharmacother., 16 (17), 2637–51. Doi: 10.1517/14656566.2015.1100170.

22. Semasinghe Bandaralage, S. P., Nirthanan, S., & Niranjan, S. (2019). Does Sotalol Still Have a Role in the Management of Arrhythmias? Am. J. Ther., 26 (1), e161–e169. Doi: 10.1097/MJT.0000000000000507.

23. Wacker-Gussman, A., Strasburger, J., Cuneo, B. F., & Wakai, R. T. (2014). Diagnosis and treatment of fetal arrhythmia. Am. journal of Perinatology, 31 (7), 617–628. Doi: 10.1055/s–0034–1372430.

24. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Himmelfarb, C. D., … WrightJr, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71 (6), 1269–1324. https://doi.org/10.1161/HYP.0000000000000066.

25. Wright, J. M., Page, R. L., & Field, M. E. (2015). Antiarrhythmic drugs in pregnancy. Cardiovasc. Ther., 13 (12). 1433–1444. Doi: 10.1586/14779072.2015.1107476.
Published
2020-05-18
How to Cite
Ivanov, V., Bulat, L., Lysunets, O., & Didik, N. (2020). The place of sotalol in the treatment of extrasystole in patients with hypertension. Reports of Vinnytsia National Medical University, 24(1), 84-91. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2020-24(1)-16

Most read articles by the same author(s)